Life Sciences News | BioTuesdays by Kilmer Lucas IR

Developments

Atossa to acquire stake in Dynamic Cell Therapies

Atossa Therapeutics (NASDAQ:ATOS) is acquiring 19.99% of the capital stock of closely-held Dynamic Cell Therapies for $2-million, in addition to $3-million previously paid to Dynamic, “This investment in Dynamic...

November 1, 2022

Markets

Maxim ups Reviva PT to $10 on rising Phase 3 enrollment

Maxim Group raised its price target for Reviva Pharmaceuticals (NASDAQ:RVPH) to $10 from $3 after the company’s ongoing Phase 3 study in schizophrenia reached more than 30% enrollment, of total 400 patients, at sites in...

November 1, 2022

Developments

Rhythm Pharma gets FDA breakthrough status in hypothalamic obesity

Rhythm Pharmaceuticals’ (NASDAQ:RYTM) setmelanotide received breakthrough therapy designation from the FDA for the treatment of hypothalamic obesity. Hypothalamic obesity is a rare, acquired form of extreme obesity that...

November 1, 2022

Markets

Raymond James ups Eupraxia PT to $9 (Canadian) on Phase 2 EoE trial

Raymond James raised its price target for Eupraxia Pharmaceuticals (TSXV:EPRX) to $9 (Canadian) from $7 and reiterated its “outperform” rating after the company initiated a Phase 2 clinical trial in eosinophilic...

October 31, 2022

Developments

SeaStar Medical completes merger with LMF Acquisition Opportunities

SeaStar Medical completed a business combination with LMF Acquisition Opportunities (NASDAQ:LMAO), a special purpose acquisition company sponsored by LM Funding America (NASDAQ:LMFA). The combined company was renamed...

October 28, 2022

Developments

OpSens starts SavvyWire study in Europe

OpSens (TSX:OPS; OTCQX:OPSSF) announced the successful completion of the first cases in a clinical study, named SAFE-TAVI, studying SavvyWire left ventricular rapid pacing in transcatheter aortic valve replacement...

October 26, 2022

Developments

Hepion Pharmaceuticals Phase 2a AMBITION results published

The peer-reviewed journal, Hepatology Communications, has published a paper by Harrison et al. entitled, “Rencofilstat, a cyclophilin inhibitor: A phase 2a, multicenter, single-blind, placebo-controlled study in...

October 26, 2022

Markets

Cantor starts Mainz Biomed at OW; PT $15

Cantor Fitzgerald launched coverage of Mainz Biomed B.V. (NASDAQ:MYNZ) with an “overweight” rating and 12-month price target of $15. The stock closed at $6.63 on Oct. 24. MYNZ develops market-ready molecular genetic...

October 25, 2022

Developments

IntelGenx receives FDA GDUFA date for partnered buprenorphine buccal film

IntelGenx’s (TSX:IGX; OTCQB:IGXT) previously undisclosed development candidate, buprenorphine buccal film, for which an abbreviated new drug application (ANDA) has been filed by Chemo Research through its agent and...

October 25, 2022

Developments

PharmaJet gets USAID contract to evaluate needle-free delivery in polio shots

Closely-held PharmaJet received a multi-year, $1.5-million grant from the United States Agency for International Development (USAID) to evaluate the impact of intradermal vaccine administration using the company’s...

October 24, 2022

Developments

AUM Biosciences going public through merger with Mountain Crest Acquisition

Closely-held AUM Biosciences, which is advancing a broad portfolio of precision oncology therapeutics, entered into a definitive business combination agreement with Mountain Crest Acquisition Corp. V (NASDAQ:MCAG). The...

October 21, 2022

Developments

Hepion Pharma food effect study with rencofilstat published

The peer-reviewed journal, Clinical Pharmacology in Drug Development, published the results of a clinical trial examining the effect of food on the oral bioavailability of Hepion Pharmaceuticals’ (NASDAQ:HEPA) lead drug...

October 21, 2022

Atossa to acquire stake in Dynamic Cell Therapies

Maxim ups Reviva PT to $10 on rising Phase 3 enrollment

Rhythm Pharma gets FDA breakthrough status in hypothalamic obesity

Raymond James ups Eupraxia PT to $9 (Canadian) on Phase 2 EoE trial

SeaStar Medical completes merger with LMF Acquisition Opportunities

OpSens starts SavvyWire study in Europe

Hepion Pharmaceuticals Phase 2a AMBITION results published

Cantor starts Mainz Biomed at OW; PT $15

IntelGenx receives FDA GDUFA date for partnered buprenorphine buccal film

PharmaJet gets USAID contract to evaluate needle-free delivery in polio shots

AUM Biosciences going public through merger with Mountain Crest Acquisition

Hepion Pharma food effect study with rencofilstat published

General

More